Paul H. Fischer 410 0 410 6 265 681 380 7.9 0 0 0.43 1,209.30 68.2 15.1 GENZYME CORP Henri A. Termeer 1,579 1,963 3,541 116 10,117 13,774 1,504 5 0 0 66.37 4,080.40 14,238.10 4605 GERON CORP Thomas B. Okarma 535 281 816 15 2,273 3,104 510 4.9 0 670 4.67 1,797.10 711.2 2.8 GILEAD SCIENCES John C. Martin36 1,146 1,652 2,798 107 8,093 10,998 1,046 9.6 28,481.70 1,664 51.14 9,732.10 43,901.30 5335.8 GTC BIOTHERAPEUTICS Geoffrey F. Cox

Paul H. Fischer GENVEC INC 410 0 410 167 Geert R. Kersten CEL-SCI CORP 405 0 405 168 Daniel N. Swisher Jr SUNESIS PHARMACEUTICALS INC 403 0 403 169 Daniel R. Passeri CURIS INC 400 0 400 170 Christopher J. Schaber DOR BIOPHARMA INC 300 100 400 171 Eric A. Rose SIGA TECHNOLOGIES INC 400 0 400 172 Carl Spana PALATIN TECHNOLOGIES INC 390 0 390 173 Safi R. Bahcall SYNTA PHARMACEUTICALS CORP 380 0 380

495 - 495 1 1,019 1,515 475 4.1 - - 0.74 42.8 4.7 0 GENOMIC HEALTH Randal W. Scott 280 25 305 - 290 595 253 10.9 - - 22.64 28.2 592.3 64 GEN-PROBE Henry L. Nordhoff 677 668 1,346 47 2,333 3,726 645 5 2,099 1,016 62.93 53.9 2,895.10 392.7 GENVEC Paul H. Fischer 380 145 525 6 234 764 345 10.2 - - 1.47 75.4 114.6 14 GENZYME Henri A. Termeer31 1,504 2,142 3,646 106 10,880 14,632 1,432 5 20,987 - 74.44 266 20,334.50 3,813.50

Paul H. Fischer GENVEC INC 380 145 525 137 Michael N. Chang OPTIMER PHARMA INC 350 175 525 138 Robert I. Blum CYTOKINETICS INC 397 126 524 139 Carl A. Pelzel DEPOMED INC 368 150 518 140 Kenneth C. Carter AVALON PHARMA INC 385 131 517 141 Brian K. Hutchison RTI BIOLOGICS INC 414 97 512 142 Jon P. Stonehouse BIOCRYST PHARMACEUTICALS INC 399 110 509 143 Frank H. Laukien BRUKER CORP 306 200 506 144 Leslie J. Browne PHARMACOPEIA INC 393 112 505 145

and Paul H. Granger vice president and general counsel

Paul H. Johnson NASTECH PHARMACEUTICAL 239 75 314 139 Eric W. Jacobson SYNTA PHARMACEUTICALS CORP 249 65 314 140 David M. Manyak CALIPER LIFE SCIENCES INC 238 74 312 141 Mark A. Gallop XENOPORT INC 245 66 311 142 Robert A. D. Scott ATHEROGENICS INC 310 0 310 143 Curtis Keith COMBINATORX INC 235 75 310 144 John Babich MOLECULAR INSIGHT PHARMA 308 0 308 145 William S. Craig CADENCE PHARMACEUTICALS INC 229 77 306 146 Charles T. Nomides BARRIER

Paul H. Johnson 239 75 314 3 233 550 0 58 NEKTAR THERAPEUTICS David Johnston 336 120 455 10 237 702 0 41 NEOPHARM INC Imran Ahmad 294 0 294 261 15 375 0 0 NEOSE TECHNOLOGIES INC David A. Zopf 276 138 414 6 157 577 0 89 NEUROBIOLOGICAL TECHN Lisa U. Carr 275 55 330 15 0 345 0 0 NEUROCRINE BIOSCIENCES Wendell Wierenga (28) 385 0 385 16 421 822 0 24 NEUROGEN CORP Stephen Uden 338 102 441 25 133 599 0 0 NITROMED INC L. G. Letts

Company Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long- Term Comp. ($000) Total Direct Comp. ($000) Base Salary Prior FY ($000) Percent Change In Base Salary Value Realizable On Exercise Of Options ($000) Value Realized On Vesting Of Restricted Stock ($000) Percentage Of Company Shares Owned by CEO Stock Price 12/31/05 Stock Price 12/31/06 Percent Change in Stock Shares Out (M) FYE Market Cap ($M) FY Revenues ($M) AASTROM BIOSCIENCES INC R. Douglas

For The 273 CEOs In BioWorld's Company Survey Who Received A Full Year Of Compensation (Base Salary Plus Bonus) Rank Executive Company Name Base Salary ($000) Bonus ($000) Total ($000) Stock Price 12/31/06 Shares Out (M) Approx. Mkt. Cap. 12/31/06 1 Kevin W. Sharer AMGEN INC 1,483 4,525 6,008 68.31 1,166.0 61,332.5 2 Arthur D. Levinson GENENTECH INC 995 2,725 3,720 81.13 1,053.0 83,179.0 3 Henri A. Termeer GENZYME CORP 1,432 1,726 3,157 61.58 263.0 16,631.6 4

With those early stage prospects in mind, Overell, along with Patrick Stayton and Allan Hoffman, both of the University of Washington's department of bioengineering, as well as Oliver Press, of the Fred Hutchinson Cancer Research Center, and Paul H. Johnson, the company's chief scientific officer, created PhaseRx, which began its corporate existence in 2006 with the licensing of a polymer technology from Stayton's and Hoffman's laboratories at UW

ISCO entered into a research agreement with Paul H. Chen, who has developed the cell transfer technology

Graham Lidgard 275 35 310 2 0 312 208 81 Nastech Pharmaceutical Paul H. Johnson 230 78 308 0 0 308 96 322 Nektar Therapeutics David Johnston 314 129 443 16 0 460 177 41 NeoPharm Inc

275 35 310 99 Paul H. Johnson Nastech Pharmaceutical 230 78 308 100 L. Gordon Letts NitroMed Inc

Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FTE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Stock Price 12/31/04 ($) Stock Price 12/31/05 ($) Percent Change Stock Price (%) Shares Out ($M) Approx. Long-Term Mkt. Cap. 12/31

For The 244 CEOs In BioWorld's 269-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) Stock Price 12/31/05 Shares Out (M) Approx. Mkt. Cap. 12/31/05 ($M) 1 Kevin W. Sharer Amgen Inc. 1,390 4,500 5,890 78.86 1,224.0 96,524.6 2 Henri A. Termeer Genzyme Corp. 1,365 1,760 3,125 70.78 259.3 18,350.3 3 Arthur D. Levinson Genentech Inc. 976 2,000 2,976 92.50 1053.7 97,468.5 4 Tony L

Paul H. Johnson (17) 250 56 306 0 0 306 0 82 Nektar Therapeutics David Johnston (18) 300 84 384 50 0 434 450 0 Neopharm Inc

250 57 307 84 Paul H. Johnson (17) Nastech Pharmaceutical Co

Company Name of Executive Age Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-term Compensation ($000) Total Direct Compensation ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Potential Realizable Value of Option Grants ($000) FTE Value of Exercisable In-the-Money Options ($000) Percent of Co. Stock Owned By CEO (%) Stock Price 12/31/03 ($) Stock Price 12/31/04 ($) Percent Change Stock Price (%) Shares Out ($M) Approx. Long-Term Mkt. Cap. 12/31

For The 237 CEOs In BioWorld's 264-Company Survey Who Received A Full Year Of Compensation Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) Stock Price 12/31/04 Shares Out (M) Approx. Mkt. Cap. 12/31/04 ($M) 1 Kevin W. Sharer Amgen Inc. 1,302 3,662 4,964 64.15 1,260.00 80,829.00 2 Joseph A. Sorge Stratagene Corp. 771 2,442 3,212 7.75 22 170.7 3 Henri A. Termeer Genzyme Corp. 1,300 1,770 3,070 58.07 249 14,460.50 4 Frank Baldino Jr